Insider Selling: Clover Health Investments (NASDAQ:CLOV) VP Sells $103,200.00 in Stock

Clover Health Investments, Corp. (NASDAQ:CLOV) VP Joseph Frank Oldakowski sold 20,000 shares of Clover Health Investments stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $5.16, for a total value of $103,200.00. Following the transaction, the vice president owned 279,067 shares in the company, valued at $1,439,985.72. This trade represents a 6.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Joseph Frank Oldakowski also recently made the following trade(s):

• On Tuesday, June 16th, Joseph Frank Oldakowski sold 12,102 shares of Clover Health Investments stock. The stock was sold at an average price of $4.86, for a total value of $58,815.72.

Clover Health Investments Stock Performance

Shares of CLOV stock opened at $4.56 on Thursday. The company has a market capitalization of $2.42 billion, a P/E ratio of -91.18 and a beta of 2.47. The company’s 50 day moving average price is $4.42 and its two-hundred day moving average price is $3.60. Clover Health Investments, Corp. has a 52 week low of $1.58 and a 52 week high of $5.59.

Clover Health Investments (NASDAQ:CLOV) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.01. Clover Health Investments had a negative net margin of 0.74% and a negative return on equity of 4.20%. The company had revenue of $743.17 million during the quarter, compared to analysts’ expectations of $728.27 million. Analysts forecast that Clover Health Investments, Corp. will post 0.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CLOV shares. Wall Street Zen cut Clover Health Investments from a “strong-buy” rating to a “buy” rating in a report on Sunday, August 16th. Zacks Research upgraded Clover Health Investments to a “hold” rating in a report on Monday. Deutsche Bank Aktiengesellschaft initiated coverage on Clover Health Investments in a research report on Thursday, September 10th. They set a “buy” rating and a $6.00 price objective for the company. UBS Group lifted their target price on Clover Health Investments from $4.75 to $5.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group boosted their target price on Clover Health Investments from $4.20 to $5.50 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $4.75.

Hedge Funds Weigh In On Clover Health Investments

Several hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new stake in Clover Health Investments during the 2nd quarter valued at $6,346,000. Tidal Investments LLC acquired a new position in shares of Clover Health Investments in the second quarter valued at $2,156,000. Lazard Asset Management LLC bought a new position in shares of Clover Health Investments in the first quarter valued at about $309,000. WINTON GROUP Ltd acquired a new stake in shares of Clover Health Investments during the 2nd quarter worth about $913,000. Finally, AXQ Capital LP grew its stake in Clover Health Investments by 602.6% in the 2nd quarter. AXQ Capital LP now owns 146,569 shares of the company’s stock valued at $768,000 after buying an additional 125,708 shares during the last quarter. Institutional investors own 19.77% of the company’s stock.

Clover Health Investments Company Profile

Clover Health Investments, Inc is a healthcare technology and insurance company focused on providing Medicare Advantage plans to eligible Medicare beneficiaries. Its insurance business offers medical coverage and related healthcare benefits through plans available in select counties across the United States.

The company also develops and uses Clover Assistant, a technology platform designed to support physicians with patient information, clinical insights, care recommendations and tools intended to help improve healthcare outcomes.